Actio Biosciences launches trial of precision medicine for rare childhood epilepsy
Actio Biosciences has launched a Phase 1b/2 clinical trial of ABS-1230, an investigational precision medicine for KCNT1-related epilepsy. KCNT1-related epilepsy is a…
Actio Biosciences has launched a Phase 1b/2 clinical trial of ABS-1230, an investigational precision medicine for KCNT1-related epilepsy. KCNT1-related epilepsy is a…
Thousands of times per year, a family’s moment of joy turns to unexpected grief. A seemingly healthy infant stops smiling or making…
Scientists have identified a key biological driver of one of the most lethal brain tumours in young children, in findings that could…
Twins often don’t pick up new skills quite as fast as single-born children in their early years, according to the findings of…
No matter where we turn on social media, short videos are everywhere. Repeated exposure to this brief, information-dense, and rewarding content stimulates…